Glonghui March 23 丨 Lyon published a report saying that Sansheng Pharmaceutical (1530.HK)'s revenue increased 7.5% year-on-year last year, and net profit increased 16% year-on-year, all higher than the bank's and market expectations, mainly due to stronger sales and increased foreign exchange earnings. The bank expects the company's product sales to grow further this year, mainly taking into account the reduced impact of the COVID-19 pandemic, particularly the impact on ISEP, and the growth of its pharmaceuticals. The target price was raised from HK$5.75 to HK$9.33, maintaining the “outperform the market” rating. Sansheng Pharmaceutical is now down 3.6% to HK$776, with a total market value of HK$18.9 billion.
大行评级 | 里昂：上调三生制药目标价至9.33港元 评级“跑赢大市”
Big Bank Ratings | Lyon: Sansheng Pharmaceutical raised its target price to HK$9.33 to “outperform the market”
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.